Market Newsdesk

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025.

Conference details are as follows:

H.C. Wainwright “HCW@Home with vTv Therapeutics”

Format: Fireside Chat
Moderator: Emily Bodnar, Director, H.C. Wainwright
vTv Therapeutics Speakers:

• Paul Sekhri, Chairman of the Board, President & Chief Executive Officer
• Thomas Strack, MD, Chief Medical Officer
• Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer
• Michael Tung, MD, MBA, Chief Financial Officer

Date: Thursday, June 12, 2025
Time: 10:00 AM ET
Webcast Link: Register here

The webcast of the event will be accessible from News & Events page of the vTv website.

About vTv Therapeutics
vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

Investor Contact

John Fraunces
LifeSci Advisors, LLC
917-355-2395
[email protected]

Media Contact

Caren Begun
TellMed Strategies
201-396-8551
[email protected]

—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC—

—Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners Continue—

TEL AVIV, Israel, June 11, 2025 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it has obtained confirmation from the FDA on two significant development milestones as the company continues to finalize the nebokitug Phase 3 program.

As part of the FDA End-of-Phase 2 (EOP2) review process, Chemomab and the FDA addressed multiple Chemistry, Manufacturing, and Controls (CMC) topics critical to ensuring the quality and consistency of drug supply for the late-stage development and eventual commercialization of nebokitug. Following productive discussions, the FDA indicated agreement with the CMC strategy proposed by Chemomab and its contract manufacturing partner.

Chemomab also engaged in a Type C meeting with the FDA to address the non-clinical fetal and embryo developmental toxicology studies that are part of the new drug regulatory pathway. Importantly, the FDA agreed that this toxicology testing may be conducted in parallel with the nebokitug Phase 3 clinical trial and be submitted as part of the planned Biologics Licensing Application (BLA). This represents a favorable outcome for Chemomab, and the FDA’s flexibility supports the timely advancement of the program.

Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab, commented, “Following up on our positive and constructive interactions with the FDA in December regarding the design of the proposed nebokitug PSC Phase 3 pivotal trial, we have further aligned on two additional significant milestones–CMC requirements needed for manufacturing of drug supply for the “to be marketed” formulation and the timing of non-clinical toxicology testing. We look forward to continuing to work closely with the FDA as we finalize the details of the proposed Phase 3 development program and continue our discussions with potential strategic partners.”

About Nebokitug

Nebokitug (CM-101) is a first-in-class dual activity monoclonal antibody that neutralizes CCL24, a soluble protein that helps drive the inflammatory and fibrotic pathways central to primary sclerosing cholangitis (PSC) and other fibro-inflammatory diseases. By inhibiting CCL24, nebokitug blocks immune cell recruitment and fibroblast activation, thereby interrupting the self-reinforcing cycle that results in fibrosis. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of nebokitug in patients, including the Phase 2 SPRING trial in patients with PSC. This study achieved the primary safety endpoint and nebokitug-treated patients with moderate/advanced disease showed improvements on a wide range of disease-related secondary endpoints. The results of the Open Label Extension portion of the SPRING trial, where PSC patients received nebokitug for up to a total of 48 weeks, confirmed and extended the initial Phase 2 results. Nebokitug has received FDA and EMA Orphan Drug designations for the treatment of PSC and systemic sclerosis and FDA Fast Track status for the treatment of PSC in adults.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “estimate,” “intend,” “may,” “plan,” “potentially,” “will” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: the risk that certain acknowledgements from the End-of-Phase 2 (EOP2) meeting with the FDA in connection with PSC regulatory approval may not materialize into a pathway for regulatory approval; that certain conclusions and assumptions drawn from the EOP2 meeting with the FDA discussed in the press release may prove incorrect and adversely affect the ability for nebokitug to become an FDA fully approved therapy; the risk that the full data set from the nebokitug study or data generated in further clinical trials of nebokitug may not be consistent with the results of the nebokitug Phase 2 PSC trial; failure to obtain, or delays in obtaining, regulatory approvals for nebokitug in the U.S., Europe or other territories; failure to successfully commercialize nebokitug, if approved by applicable regulatory authorities, in the U.S., Europe or other territories, or to maintain U.S., European or other territory regulatory approval for nebokitug if approved; uncertainties in the degree of market acceptance of nebokitug by physicians, patients, third-party payors and others in the healthcare community; development of unexpected safety or efficacy concerns related to nebokitug; failure to successfully conduct future clinical trials for nebokitug, including due to the Company’s potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things; risks that the Company’s clinical studies will be delayed or that serious side effects will be identified during drug development; failure of third parties on which the Company is dependent to manufacture sufficient quantities of nebokitug for commercial or clinical needs, to conduct the Company’s clinical trials; changes in laws and regulations applicable to the Company’s business and failure to comply with such laws and regulations; business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises; and uncertainties with respect to the Company’s need and ability to access future capital; and the intensity and duration of the current war in Israel, and its impact on our operations in Israel. These risks are not exhaustive. You should carefully consider the risks and uncertainties described in the “Risk Factors” sections of our 20-F for the year ended December 31, 2024. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release. Before you invest, you should read the documents we have filed and will file with the SEC for more complete information about us. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities law of any such state or jurisdiction.

About Chemomab Therapeutics Ltd.

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of nebokitug in patients. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug PSC Phase 3 trial. The design of Phase 3 calls for a single pivotal trial based on a clinical event primary endpoint that provides a clear and streamlined pathway to potential full regulatory approval. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s nebokitug program for the treatment of systemic sclerosis has an open U.S. IND. For more information, visit: chemomab.com.
  
Contact:

Media and Investors:

Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
[email protected]
[email protected]

CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) — Americans who relocated in 2024 sought out new locales, with the three most popular locations in the state of Texas—North Houston, Fort Worth and Austin. Overall, consumers left pricier and densely populated urban areas in favor of more affordable cities and suburbs in the southern U.S., according to TransUnion (NYSE: TRU) research focused on migration and its implications for insurers.

While migration rates have decreased steadily since pre-pandemic 2019, a significant number of consumers are making bold moves. More than a quarter (26%) of Americans who moved in 2024 relocated by distances ranging from 51 miles to 250 miles and beyond.

“As consumers continue to find new places to settle, it’s important for insurers to stay on top of the trends across segments,” said Patrick Foy, senior director of strategic planning for TransUnion’s Insurance business. “These changes can have implications for customer acquisition, risk and engagement.”

Top Five Inbound and Outbound Markets in 2024

Inbound	Outbound
North Houston, TX	Miami, FL
Fort Worth, TX	Houston, TX
Austin, TX	Queens, NY
Phoenix, AZ	South Florida, FL
Nashville, TN	Oakland, CA

Gen Z goes against the grain


The research found migration trends among consumers aged 30 and older largely held true. The majority left locales like New York, Chicago and Miami, with some slight variations in where they ended up. Baby Boomers and Silent Generation consumers primarily moved to smaller locales in South Carolina and Florida. Gen Xers also moved to those states, but Texas was their top destination. Millennials seemed to avoid Florida, instead dispersing across suburban markets Texas and North Carolina.

However, many Gen Z consumers moved in the opposite direction, landing in the same cities older Americans were leaving, like New York and Chicago.

“Gen Z’s migration patterns more closely reflect those of Millennials back in 2010,” said Foy. “And they are likely going for the same reasons: the allure of big city living and the prospect of work opportunities to help launch their careers.”

Staying connected to life insurance beneficiaries


When consumers move across state lines, public records do not always update accordingly. This can create problems for life insurance providers who then may not be able to locate a beneficiary or receive notification of death for their policyholder.

The majority of states require life insurers to monitor mortality status of policy holders and to conduct due diligence to contact beneficiaries. However, over recent years the federal government has limited access to the Social Security Death Master File (SS DMF). Those records now account for only 12% of TransUnion’s deceased file data—compared to 2010 when they accounted for 95%. 

Additionally, nearly six out of 10 consumers don’t even know how to find out if they are the beneficiary of a life insurance policy. This is underscored by the fact that each year tens of millions of dollars in life insurance payments go unmatched with beneficiaries.¹

TransUnion’s TruLookup™ Deceased Data utilizes multiple sources, including TransUnion proprietary data, obituary data, funeral home listings, state level sources, and more. Insurers who rely solely on the SS DMF are at a significant disadvantage for uniting benefits to beneficiaries.

“Life insurance companies that rely on public records alone will likely fail to deliver on their promise to customers,” said Karen Malone, senior director of strategic planning for TransUnion’s life insurance business. “They need a robust identity solution to give them real time updates on the status of their insureds and the location of their beneficiaries.”

Understanding a driver’s risk


Similarly, when a consumer with prior traffic violations moves to a new state or receives a traffic violation outside of their license state, their motor vehicle report (MVR) does not always capture those events.

Prior TransUnion research found that violations increased by 8% in 2024 compared to 2023—their highest point since the onset of the coronavirus pandemic. The study highlighted the strong correlation between traffic enforcement and roadway safety, along with reaffirming the power of violation data to predict future insurance losses.

TransUnion research notes that auto insurers should look beyond MVRs and investigate court records when assessing the risk of a new customer as they are less expensive than MVRs and provide a more comprehensive history. In addition, traffic violations have reached their highest point since the onset of the coronavirus pandemic, suggesting there are increasingly more insights into drivers’ behavior on the road.

Learn more about TransUnion Insurance Risk solutions, including TruVision™ Driving History, here.
Learn more about TransUnion solutions for life insurance here.

1. “What to Know About Life Insurance Beneficiaries,” National Association of Insurance Commissioners, September 12, 2023

About TransUnion (NYSE: TRU)

TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good^® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world. http://www.transunion.com/business

Contact	Dave Blumberg TransUnion
E-mail	[email protected]
Telephone	312-972-6646

SAN FRANCISCO, June 11, 2025 (GLOBE NEWSWIRE) — Meltwater, a global leader in media, social and consumer intelligence, today announces a partnership with 8×8, Inc. (NASDAQ: EGHT) through the 8×8 Technology Partner Ecosystem, empowering businesses to connect with customers through social media more efficiently, enhance service operations, and deliver superior customer experiences.

8×8^® is the industry’s most integrated platform provider for CX, which combines Contact Center, Unified Communication and CPaaS solutions, and supports enterprise organizations around the world with its suite of CX solutions. With Meltwater’s social insights available directly within 8×8 Contact Center™, 8×8 customers can now utilize social media as a customer care and engagement channel. Social media is a critical channel for customer engagement, but many contact centers lack the necessary tools to monitor and analyze the vast volume of customer interactions happening online. This new solution with 8×8 addresses this gap, equipping teams with the tools needed to make sense of the ever-growing mountain of social data.

By leveraging Meltwater’s industry leading dataset, which processes more than 1 billion pieces of content daily and transforms them into actionable insights, teams can respond to inquiries faster, identify emerging risks, and extend their reach to underserved audiences, enhancing the overall customer experience.

Key benefits of the integration include:

• Advanced and configurable filtering: Use advanced keyword filtering to surface the most relevant and actionable social media conversations – such as @mentions and direct messages – and seamlessly route them to existing 8×8 Contact Center agent queues, just like any other channel.
• Elevated customer experience across social channels: Enable faster, personalized responses and consistent engagement across platforms.
• Streamlined agent workflows: Unify social and support channels to reduce app switching and improve resolution times.
• Boosted brand reputation and loyalty: Identify negative sentiment early, respond quickly, and amplify praise to elevate customer experience and strengthen customer trust.

“Today’s customers expect fast personalized responses, especially on social media. When mentions go unanswered or replies are delayed, it doesn’t just mean missed opportunities, it can erode trust and damage brand reputation,” said Doug Balut, Senior Vice President of Global Alliances and Partnerships at Meltwater. “This partnership brings together two industry leaders to empower brands with real-time insights they need to understand customer sentiment, anticipate issues, and respond with agility to improve the customer experience.”

“Social media has become a vital channel for customer engagement, yet many contact centers still struggle to support it effectively,” said Victor Belfor, Global Vice President, Business Development and Strategic Partnerships at 8×8, Inc. “We chose to partner with Meltwater because we believe it’s one of the most powerful social listening platforms in the market. Together, we’re helping organizations stay connected with their customers by delivering best-in-class technology from a single, trusted provider.”

The integration between 8×8 and Meltwater reflects the core strength of the 8×8 Technology Partner Ecosystem: delivering powerful, proven technologies without compromising the simplicity and reliability of a single-source solution. Joint customers benefit from a seamless, deeply integrated experience that feels native to the 8×8 platform, while still gaining access to cutting-edge capabilities helping businesses streamline operations, reduce total cost of ownership (TCO), and avoid the pitfalls of fragmented tech stacks.

For more information, please contact:

Stacy Slayden
[email protected]

About Meltwater


Meltwater
empowers companies with solutions that span media, social and consumer intelligence. By analyzing ~1 billion pieces of content daily and transforming them into vital insights, Meltwater unlocks the competitive edge to drive results. With 27,000 global customers, 50 offices across six continents, and 2,200 employees, Meltwater is the industry partner for global brands making an impact. Learn more at meltwater.com.

About 8×8 Inc.

8×8, Inc. (NASDAQ: EGHT) connects people and organizations through seamless communication on the industry’s most integrated platform for Customer Experience—combining Contact Center, Unified Communication, and CPaaS solutions. The 8×8^® Platform for CX integrates AI at every level to enable personalized customer journeys, drive operational excellence and insights, and facilitate team collaboration. We help customer experience and IT leaders become the heartbeat of their organizations, empowering them to unlock the potential of every interaction. For additional information, visit www.8×8.com, or follow 8×8 on LinkedIn, X, and Facebook. 8×8 and associated logos and marks are trademarks of 8×8, Inc. All rights reserved.

New York, NY, June 11, 2025 (GLOBE NEWSWIRE) — Mercurity Fintech Holding Inc. (the “Company,” “we,” “us,” “our company,” or “MFH”) (Nasdaq: MFH), a digital fintech group, today announced its plans to raise $800 million to establish a long-term Bitcoin treasury reserve. Through this fundraising effort, MFH aims to leverage its established expertise in blockchain-driven financial infrastructure to strategically acquire and manage Bitcoin assets. The Company also plans to integrate these holdings into its digital reserve framework through blockchain-native custody, staking integration, and tokenized treasury management services.

Additionally, through this fundraising effort, the Company intends to systematically build a Bitcoin reserve position and implement an integrated digital asset treasury framework. This will involve deploying institutional-grade custodial infrastructure, blockchain-native liquidity protocols, and staking-enabled capital efficiency tools. The objective is to transition a portion of the Company’s treasury into a yield-generating, blockchain-aligned reserve structure that reinforces long-duration asset exposure and balance sheet resilience.

“We’re building this Bitcoin treasury reserve based on our belief that Bitcoin will become an essential component of the future financial infrastructure,” said Shi Qiu, CEO of the Company. “We are positioning our company to be a key player in the evolving digital financial ecosystem.”

Concurrently, according to FTSE Russell’s preliminary 2025 annual reconstitution list, the Company is poised to be included in the broad-market Russell 3000^® and Russell 2000^® Index, representing an upgrade from its prior classification within the Russell Microcap Index. The index reclassification and upgrade could broaden the Company’s exposure to institutional investors, including those managing index-linked and actively managed funds. Furthermore, the Company believes that such inclusion signals to the market that MFH is demonstrating consistent execution capability and growing relevance of its blockchain-based infrastructure strategy within the public markets.

“Moving from the Russell Microcap to the Russell 2000 shows that investors recognize the value we are creating in blockchain finance,” Qiu added. “Our Bitcoin treasury reserve initiative is the next logical step in this evolution.”

About Mercurity Fintech Holding Inc.

Mercurity Fintech Holding Inc. (NASDAQ: MFH) is a fintech group powered by blockchain infrastructure, offering technology and financial services. Through its subsidiaries including Chaince Securities, LLC, MFH aims to bridge traditional finance and digital innovation, offering services spanning digital assets, financial advisory, and capital markets solutions.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.

Contacts:

International Elite Capital Inc.
Annabelle Zhang
Tel: +1(646) 866-7928
Email: [email protected]

Waltham, Massachusetts, June 11, 2025 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension” or the “Company”), a leader in Digital Manufacturing solutions, has appointed two technology and growth experts, Andy Sriubas and Eileen Tanghal, to its Board of Directors. The appointments come at a pivotal moment as the Company shifts from M&A integration to scaling a unified technology platform across its global markets.

“We are strengthening our board at a critical moment in Nano Dimension’s development,” said Ofir Baharav, CEO, Nano Dimension. “With our digital manufacturing platform now aligned and abundant opportunities in front of us, Andy and Eileen bring forward-thinking leadership and operational experience that will help guide our next phase with a focus on delivering for shareholders. Both bring a deep understanding of technology at its core and a broad perspective on how to translate it into value.”

Andy Sriubas is a veteran commercial executive and former chief commercial officer at OUTFRONT Media, where he led digital transformation, strategic partnerships, and new revenue generation. He previously spent over two decades as an investment banker with JPMorgan, UBS, and DLJ, advising on complex M&A and capital markets transactions. Sriubas earned a bachelor of science degree in finance at Boston College’s Wallace E. Carroll School of Management. His professional certificates include Stanford Law School, Board of Directors College; MIT xPro in Quantum Mechanics; and MIT Sloan School of Management in Blockchain Technology. He is located in South Carolina.

Eileen Tanghal is co-founder and general partner at venture capital firm Black Opal Ventures, with deep expertise in evaluating and scaling breakthrough technologies. A former partner at In-Q-Tel, a venture capital firm established by the Central Intelligence Agency, and executive at ARM and Applied Materials Ventures, she brings a unique ability to assess technical foundations and translate them into scalable, disruptive outcomes. Tangal earned her MBA in International Finance and Entrepreneurial Management from the London Business School, and a bachelor’s degree in electrical engineering and computer science from the Massachusetts Institute of Technology. She is based in the Silicon Valley area.

“My career has largely been dedicated to leveraging platform technologies and helping companies to successfully navigate digital transformation,” said Sriubas. “This is a transformative period for Nano Dimension with the Company’s expanded technology portfolio and renewed focus on execution presenting a unique opportunity to shape the future of digital manufacturing. I look forward to contributing my expertise to help accelerate growth, unlock value, and scale innovation that truly matters.”

“Nano Dimension is at an important inflection point in its growth and focus on commercialization in the digital manufacturing market,” said Tanghal. “Like so many of the companies I have supported over the decades, it is on the cusp of using technology to solve many of the global manufacturing industries’ largest problems. Its seasoned management team and broad array of patents, technologies and proven solutions have set the Company up for success.”

Bob Pons, chairman of the board of Nano Dimension, added: “Andy and Eileen bring complementary strengths—Andy in commercializing platforms and navigating strategic opportunities and Eileen in identifying and scaling transformative technologies. Together, they add depth to the Company’s existing board, bringing strategic foresight and real-world operating acumen at a moment when Nano Dimension solidifies its digital manufacturing leadership and is primed for growth.”

About Nano Dimension

Driven by strong trends in onshoring, national security, and increasing product customization, Nano Dimension (Nasdaq: NNDM) delivers advanced Digital Manufacturing technologies to the defense, aerospace, automotive, electronics, and medical devices industries, enabling rapid deployment of high-mix, low-volume production with IP security and sustainable manufacturing practices.

For more information, please visit https://www.nano-di.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding Nano’s future growth, strategic plan and value to shareholders, and all other statements other than statements of historical fact that address activities, events or developments that Nano intends, expects, projects, believes or anticipates will or may occur in the future. Such statements are based on management’s beliefs and assumptions made based on information currently available to management. These forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company’s actual results and performance to be materially different from those expressed or implied in the forward-looking statements. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates and uncertainties that are difficult to predict. Because such statements deal with future events and are based on the current expectations of Nano, they are subject to various risks and uncertainties. The forward-looking statements contained or implied in this communication are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Nano’s annual report on Form 20-F filed with the Securities and Exchange Commission (the “SEC”) on May 12, 2025, and in any subsequent filings with the SEC. Except as otherwise required by law, Nano undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this communication.

# # #

Editor’s note: High-resolution photos of new board members
Andy Sriubas and Eileen Tanghal are available upon request.

Contacts:

Investors: ICR – [email protected]
Media: Feintuch Communications – [email protected]

— PCRX-201 demonstrated sustained clinical efficacy with improvements in pain, stiffness, and function for up to three years –

BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new long-term follow-up data from its Phase 1 clinical trial evaluating PCRX-201 (enekinragene inzadenovec), a novel gene therapy candidate for osteoarthritis of the knee. Results show that a single intra-articular injection of PCRX-201 was well tolerated and produced sustained improvements in pain, stiffness, and function through 156 weeks in patients with moderate-to-severe osteoarthritis of the knee.

The study findings will be presented during a poster session at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, on Wednesday, June 11, from 3:30 to 4:30 PM CET.

“The three-year data from this trial underscore the potential of PCRX-201 to meaningfully change the treatment paradigm for patients living with osteoarthritis of the knee,” said Philip G. Conaghan, Professor of Musculoskeletal Medicine at the University of Leeds and lead author on the study. “Current osteoarthritis treatments target its symptoms and are limited to three to six months of pain relief. With PCRX-201, we are targeting chronic inflammation at the cellular level to address a root cause of osteoarthritis. Providing three or more years of improvements in pain and function while potentially modifying the disease with a single intraarticular injection would be transformative for patients, physicians, and the healthcare system.”

PCRX-201 features an innovative design based on the company’s proprietary high-capacity adenovirus, or HCAd, gene therapy vector platform. It is injected locally into the knee joint to boost cellular production of interleukin-1 receptor antagonist (IL-1Ra), and block interleukin-1 pathway activation to improve chronic inflammation, pain, and function. PCRX-201’s unique disease-modifying design also features an inducible promoter to mimic the body’s natural response to inflammation by “turning up” the expression of IL-1Ra when inflammation is present in the joint and turning down expression once inflammation is quelled.  

Study Details

The open-label, Phase 1 trial investigated the safety and efficacy of PCRX-201 administered by ultrasound-guided intra-articular injection in 72 patients aged 30 to 80 who remained in the trial for 156 weeks. Participants were divided into two cohorts. The first cohort (N=36) was administered one injection of PCRX-201 at a low, middle or high dosage. The second cohort (N=36) received concurrent pretreatment with an intra-articular corticosteroid (methylprednisolone 40 mg) to improve tolerability and gene transfer. Knee pain, stiffness and function were assessed at 156 weeks using the Western Ontario and McMaster Universities Osteoarthritis Index pain score (WOMAC-A), the stiffness score (WOMAC-B), and the Knee Injury Osteoarthritis Outcome Score (KOOS), respectively.

Key Findings:

• A single injection of PCRX-201 at any dose level had an acceptable safety profile and was not associated with any serious treatment-related adverse events.
• Patients experienced sustained, clinically meaningful reductions in pain and stiffness and improvements in function for three years.
• Least squares mean (LSM) improvements from baseline in the corticosteroid-pretreated cohort across all PCRX-201 doses included:
  • 51–53% reduction in WOMAC-A pain scores
  • 38–76% reduction in WOMAC-B stiffness scores
  • 26–28-point improvements in KOOS daily living function scores
• The findings suggest lower doses of PCRX-201 may be effective and support ongoing investigation in Phase 2 studies.

No serious treatment-emergent AEs related to the treatment or procedure were reported regardless of steroid pretreatment or dose level administered. Treatment-related joint effusions (swelling) were the most common AE, occurring in 36% of patients who received steroid pretreatment vs 61% of patients who were not pretreated. The majority of effusions were mild to moderate in severity and resolved in a median of 33 days among patients in the pretreated group.

“PCRX-201 continues to show excellent results as a unique disease-modifying gene therapy for osteoarthritis, with the potential to transform how we manage this often-debilitating condition affecting millions of Americans,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “The three-year durability that we’ve seen so far continues to reinforce the importance of advancing PCRX-201 and potentially delivering innovative solutions to meet the longstanding unmet needs of patients living with osteoarthritis of the knee.”

In March 2024, PCRX-201 became the first-ever gene therapy product candidate in osteoarthritis to receive Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA).

RMAT designation provides the benefits of intensive FDA guidance on efficient drug development, including the ability for early interactions with the FDA to discuss surrogate or intermediate endpoints, potential ways to support accelerated approval and satisfy post-approval requirements, potential priority review of the Biologics License Application (BLA), and other opportunities to expedite development and review. PCRX-201 was also granted Advanced Therapy Medicinal Products (ATMP) designation by the European Medicines Agency in May 2023.

Given the promising Phase 1 results, dosing is underway in a Phase 2 study of PCRX-201 (the ASCEND study) for the treatment of osteoarthritis of the knee.

About PCRX-201 (enekinragene inzadenovec)

PCRX-201 (enekinragene inzadenovec) features an innovative design based on the company’s proprietary high-capacity adenovirus vector platform. It is currently being studied in the fundamental, underlying chronic inflammatory processes that contribute to “wear and tear” over time in osteoarthritis of the knee, a condition that affects more than 14 million individuals in the U.S. today.

In November 2024, Pacira reported promising data from a large Phase 1 study in which PCRX-201 provided sustained improvements in knee pain, stiffness, and function through two years following local administration, with a well-tolerated safety profile. PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency. PCRX-201 is the first gene therapy to achieve these clinical results and earn these regulatory designations in osteoarthritis of the knee – a testament to its promise and potential.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera_®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Forward-Looking Statements

Any statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the settlement described herein, ‘5×30’, our growth and business strategy; our future outlook, our intellectual property and patent terms, our growth and future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH; risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and our business, including our revenues, financial condition, cash flow and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the “SEC”). In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the SEC.

Investor Contact:
Susan Mesco, (973) 451-4030
[email protected]

Media Contact:
Sara Marino, (973) 370-5430
[email protected]

MIAMI, June 11, 2025 (GLOBE NEWSWIRE) — NextNRG, Inc. (NASDAQ: NXXT), a pioneer in AI-powered energy innovation, today announced its inclusion in the Russell 2000® and Russell 3000® Indexes, according to a list of additions published by FTSE Russell. The Company leverages advanced technologies—including its Next Utility Operating System®, smart microgrid infrastructure, wireless EV charging, and on-demand mobile fuel delivery—to transform how energy is produced, managed, and delivered.

The official reconstitution will take effect after market close on Friday, June 27, 2025. Trading in the reconstituted indexes will begin on Monday, June 30, 2025.

The Russell indexes are widely used by investment managers and institutional investors for index-based funds and benchmarking. FTSE Russell estimates that approximately $10.6 trillion in assets are benchmarked to the Russell U.S. indexes.

“This recognition marks an important milestone in our continued growth,” said Michael D. Farkas, Founder and CEO of NextNRG. “We believe that inclusion in the Russell indexes reflects our disciplined execution and growing investor recognition of NextNRG’s unique position at the convergence of efficient energy, intelligent mobility, and AI-powered infrastructure. As we scale transformative projects across the country, this expanded visibility will support deeper institutional engagement and long-term value creation.”

The Russell index reconstitution ranks the 3,000 largest U.S. stocks by total market capitalization. Companies included in the all-cap Russell 3000® Index are automatically assigned to the large-cap Russell 1000® or small-cap Russell 2000® Index, as well as relevant growth and value indexes.

NextNRG’s addition to the Russell indexes follows strong quarterly growth and strategic progress across key markets, including new state expansion, enterprise partnerships, and continued advancement of its proprietary energy infrastructure platform.

About NextNRG, Inc.

NextNRG Inc. (NextNRG) is Powering What’s Next by implementing artificial intelligence (AI) and machine learning (ML) into renewable energy, next-generation energy infrastructure, battery storage, wireless electric vehicle (EV) charging and on-demand mobile fuel delivery to create an integrated ecosystem.

At the core of NextNRG’s strategy is its Next Utility Operating System®, which leverages AI and ML to help make existing utilities’ energy management as efficient as possible; and the deployment of NextNRG smart microgrids, which utilize AI-driven energy management alongside solar power and battery storage to enhance energy efficiency, reduce costs and improve grid resiliency. These microgrids are designed to serve commercial properties, healthcare campuses, universities, parking garages, rural and tribal lands, recreational facilities, and government properties, expanding energy accessibility while supporting decarbonization initiatives.

NextNRG continues to expand its growing fleet of fuel delivery trucks and national footprint, including the acquisition of Yoshi Mobility’s fuel division and Shell Oil’s trucks, further solidifying its position as a leader in the on-demand fueling industry. NextNRG is also integrating sustainable energy solutions into its mobile fueling operations. The company hopes to be an integral part of assisting its fleet customers in their transition to EV, providing fuel delivery while advancing efficient energy adoption. The transition process is expected to include the deployment of NextNRG’s innovative wireless EV charging solutions.

To find out more visit: www.nextnrg.com

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement describing NextNRG’s goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “expect,” “intends,” “will,” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including, but not limited to, those related to NextNRG’s business and macroeconomic and geopolitical events. These and other risks are described in NextNRG’s filings with the Securities and Exchange Commission from time to time. NextNRG’s forward-looking statements involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although NextNRG’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by NextNRG. Except as required by law, NextNRG undertakes no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements.

Investor Relations Contact

NextNRG, Inc.
Sharon Cohen
[email protected]

GLEN ALLEN, Va., June 11, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing precision treatments for addiction and related disorders, today announced progress in the design and planning of its upcoming Phase 3 trial evaluating AD04, its lead investigational therapy for Alcohol Use Disorder (AUD).

As part of its Phase 3 trial preparation, Adial engaged Cytel Inc., a global leader in data science and advanced statistical methodologies for clinical trials, to provide expert support on trial design and data interrogation. Cytel’s contributions have helped inform key design elements of Adial’s upcoming trial, with the goal of maximizing efficiency, cost-effectiveness, and the likelihood of success. In part, Cytel’s efforts identified specific genetic subpopulations potentially more responsive to AD04, thereby enabling a refined Phase 3 strategy that aligns with both clinical and regulatory expectations.

Highlights:

• Precision Phase 3 Planning: Post-hoc analyses of historical clinical trial data identified genotype-defined patient subgroups likely to benefit most from AD04. This supports Adial’s precision medicine approach in the upcoming Phase 3 trial—targeting higher efficacy and commercial differentiation.
• Data-Driven, Adaptive Trial Design: Adial partnered with Cytel to apply advanced statistical analytics and simulation modelling to support a more efficient and targeted Phase 3 strategy, including machine learning and proprietary tools such as East®, to optimize the trial design, enable adaptive enrichment, and align with regulatory expectations.
• Upcoming Milestones: The precision-focused Phase 3 trial is expected to begin in late 2025, with potential for interim analysis-driven readouts, supporting a streamlined path to potential regulatory submission.

“Adial’s collaboration with Cytel reinforces our commitment to disciplined capital deployment and data-driven execution,” said Cary Claiborne, CEO at Adial. “By leveraging advanced analytics and adaptive design, we are in a strong position to generate meaningful clinical data while minimizing time and spend. We believe this strategy materially increases the probability of success for AD04 and creates significant value for patients and shareholders alike.”

Adial’s platform is focused on developing genetically targeted therapies for addiction—an area of high unmet need and growing public health urgency. The Company believes AD04 represents a first-in-class opportunity in a multi-billion-dollar global AUD market, and that its refined clinical strategy will accelerate value realization.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.

Forward Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding maximizing efficiency, cost-effectiveness, and the likelihood of success of Adial’s upcoming trial, enabling a refined Phase 3 strategy that aligns with both clinical and regulatory expectations, targeting higher efficacy and commercial differentiation in the upcoming Phase 3 trial, applying advanced statistical analytics and simulation modelling to support a more efficient and targeted Phase 3 strategy to optimize the trial design, enable adaptive enrichment, and align with regulatory expectations, beginning the Phase 3 trial later this year, the study design supporting a streamlined path to potential regulatory submission, being in a strong position to generate meaningful clinical data while minimizing time and spend by leveraging advanced analytics and adaptive design, the strategy materially increasing the probability of success for AD04 and creating significant value for patients and shareholders, developing genetically targeted therapies for addiction for Adial’s platform, AD04 representing a first-in-class opportunity in a multi-billion-dollar global AUD market, accelerating value realization through the Company’s refined clinical strategy and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Investor Contact:

Crescendo Communications, LLC

David Waldman / Alexandra Schilt

Tel: 212-671-1020

Email: [email protected]

CARLSBAD, Calif., June 11, 2025 (GLOBE NEWSWIRE) — Viasat, Inc. (NASDAQ: VSAT), a global leader in satellite communications, today announced Satélite Norte has become the first operator to trial its new Digital Bus solution allowing the major transport operator to provide high-quality passenger experiences using satellite and cellular connectivity.

Following a successful test phase the solution is now being used by Satélite Norte vehicles between Goiânia, state of Goiás, and São Paulo, more than 500 miles away in the country’s southeast. With travelers across Brazil and many other countries relying on buses where rail or air routes are either too expensive or unavailable, Digital Bus offers reliable, high-speed satellite connectivity across remote locations.

Digital Bus features a passenger portal which allows travellers to access Wi-Fi quickly and intuitively. This also enables bus operators to implement monetization strategies through targeted and dynamic advertising, as well as gather passenger feedback and insights. Digital Bus is powered by customizable, managed satellite and cellular connectivity and provides operators with an operational intelligence platform to monitor the system and other datapoints from their vehicles.

Waldir Sampaio, Executive Director of Satélite Norte, said: “We are very pleased with the performance during the test phase, especially the connection stability in more remote areas. Our partnership with Viasat aligns perfectly with our mission to offer comfort, innovation, and a differentiated experience to our passengers. We believe that high-quality onboard connectivity will become a competitive advantage and add even more value to our luxury route between Goiás and São Paulo.”

Andy Kessler, Vice President, Enterprise and Land Mobile, Viasat, said: “Across many regions of the world buses are a key transport link – particularly in places where air travel is expensive, and rail routes are lacking. After launching Digital Bus earlier this month, we are proud to partner with Satélite Norte to bring our Digital Bus solution to Brazil. Together, we’re proving that reliable connectivity is transforming the passenger experience and helping operators digitize and elevate their entire operation. As premium road travel continues to grow, internet access is no longer a luxury, it’s an essential part of the journey.”

About Viasat

Viasat is a global communications company that believes everyone and everything in the world can be connected. With offices in 24 countries around the world, our mission shapes how consumers, businesses, governments and militaries around the world communicate and connect. Viasat is developing the ultimate global communications network to power high-quality, reliable, secure, affordable, fast connections to positively impact people’s lives anywhere they are – on the ground, in the air or at sea, while building a sustainable future in space. In May 2023, Viasat completed its acquisition of Inmarsat, combining the teams, technologies and resources of the two companies to create a new global communications partner. Learn more at www.viasat.com, the Viasat News Room or follow us on LinkedIn, X, Instagram, Facebook, Bluesky, Threads, and YouTube.

About Satélite Norte

Founded in 1996 and headquartered in Goiânia, Brazil, Expresso Satélite Norte is a prominent interstate bus operator serving regions from North to South of the country. With over 100 daily departures, the company connects major cities such as Goiânia, Fortaleza, Belém, and São Paulo. Renowned for its commitment to comfort and innovation, Satélite Norte offers a modern fleet featuring premium amenities, including fully reclining seats and onboard Wi-Fi, catering to the growing demand for high-quality road travel experiences.

Copyright © 2025 Viasat, Inc. All rights reserved. Viasat, the Viasat logo and the Viasat Signal are registered trademarks in the U.S. and in other countries of Viasat, Inc. All other product or company names mentioned are used for identification purposes only and may be trademarks of their respective owners.

Viasat, Inc. Contacts

Richard Jones – External Communications, Viasat Enterprise, [email protected]
Lisa Curran/Peter Lopez, Investor Relations, [email protected]

Forward-Looking Statements

This press release contains forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933 and the Securities Exchange Act of 1934.  Forward-looking statements include, among others, statements that refer to the planned roll-out of the Digital Bus solution and its future performance or reliability. Readers are cautioned that actual results could differ materially from those expressed in any forward-looking statements.  Factors that could cause actual results to differ include our ability to successfully roll-out the Digital Bus solution; its overall reliability, availability and performance characteristics; our reliance on commercial partners to provide coverage and capacity to enable Digital Bus, our ability to realize the anticipated benefits of the ViaSat-3 class satellites and any future satellite we may construct or acquire; unexpected expenses related to our satellite projects; risks associated with the construction, launch and operation of satellites, including the effect of any anomaly, operational failure or degradation in satellite performance; our ability to successfully develop, introduce and sell new technologies, products and services; our reliance on a limited number of third parties to manufacture and supply our products; increased competition; introduction of new technologies; the effect of adverse regulatory changes (including changes affecting spectrum availability or permitted uses) on our ability to sell or deploy our products and services; changes in the way others use spectrum; our inability to access additional spectrum, use spectrum for additional purposes, and/or operate satellites at additional orbital locations; competing uses of the same spectrum or orbital locations that we utilize or seek to utilize; and other factors affecting the communications industry generally. In addition, please refer to the risk factors contained in our SEC filings available at www.sec.gov, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. We undertake no obligation to update or revise any forward-looking statements for any reason.